Despite the rapid pace of biomedical engineering research, translating developed products into clinical practice remains challenging due to regulations, manufacturing, and long-term in vivo safety. The eye offers advantageous features to lower translational hurdles, making it an ideal clinical target and an approachable testbed for biofabricated implants. However, eyes also have anatomical and physiological barriers that hinder conventional ophthalmic delivery routes, leading to poor drug bioavailability. Advances in biofabrication and biomaterials used in ophthalmic therapeutic implants have the potential to address the current challenges. This review will explore biomaterials, biofabrication methods, and possible ocular implantation sites from the perspective of developing effective therapeutic implants. It also examines clinically available products and current clinical trials, along with recent advancements and next-generation technologies in ophthalmic therapeutic delivery implants. This review aims to provide insights that facilitate the translation of emerging ocular therapeutics into clinically available treatments.
Kim et al. (Tue,) studied this question.